Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing Issues Delay Half Of Pending BLAs, CBER’s Yetter Says

Executive Summary

Half of the active pending BLAs at the Office of Therapeutics Research & Review as of Jan. 1 have manufacturing concerns, Center for Biologics Evaluation & Research Associate Director-Review Management Robert Yetter, PhD, said

You may also be interested in...



Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says

The Center for Biologics Evaluation & Research's new product review performance has been "excellent" under the user fee program, FDA said

Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says

The Center for Biologics Evaluation & Research's new product review performance has been "excellent" under the user fee program, FDA said

CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16

FDA's working group on CBER/CDER consolidation will meet for the first time the week of Sept. 16

Related Content

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel